Black Swan Sale

50% Off Elite

Register Now!

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Last Close
Nov 24  •  04:00PM ET
2.24
Dollar change
+0.11
Percentage change
5.16
%
Index- P/E- EPS (ttm)-2.35 Insider Own11.55% Shs Outstand27.68M Perf Week6.16%
Market Cap62.94M Forward P/E3.10 EPS next Y0.72 Insider Trans0.00% Shs Float24.85M Perf Month-28.89%
Enterprise Value66.17M PEG- EPS next Q0.01 Inst Own24.76% Short Float3.46% Perf Quarter-14.83%
Income-38.06M P/S262.25 EPS this Y56.96% Inst Trans3.85% Short Ratio1.83 Perf Half Y-13.18%
Sales0.24M P/B- EPS next Y171.14% ROA-391.21% Short Interest0.86M Perf YTD1.82%
Book/sh-0.93 P/C8.77 EPS next 5Y- ROE- 52W High6.01 -62.73% Perf Year85.12%
Cash/sh0.26 P/FCF- EPS past 3/5Y68.34% - ROIC- 52W Low1.15 94.78% Perf 3Y-81.64%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin42.56% Volatility9.49% 8.70% Perf 5Y-97.93%
Dividend TTM- EV/Sales275.71 EPS Y/Y TTM-9.32% Oper. Margin-6292.98% ATR (14)0.22 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.29 Sales Y/Y TTM- Profit Margin-15727.69% RSI (14)38.55 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.29 EPS Q/Q-79.11% SMA20-12.52% Beta1.96 Target Price36.50
Payout- Debt/Eq- Sales Q/Q- SMA50-23.38% Rel Volume0.54 Prev Close2.13
Employees- LT Debt/Eq- EarningsNov 17 BMO SMA200-15.86% Avg Volume471.44K Price2.24
IPODec 04, 2017 Option/ShortYes / Yes EPS/Sales Surpr.-105.79% -95.97% Trades Volume262,925 Change5.16%
Date Action Analyst Rating Change Price Target Change
Sep-08-25Initiated H.C. Wainwright Buy $40
Apr-02-25Initiated BTIG Research Buy $18
Nov-17-25 04:01PM
03:30PM
08:03AM
Nov-13-25 03:42PM
Nov-12-25 08:31AM
03:15PM Loading…
Nov-10-25 03:15PM
08:03AM
Oct-27-25 02:30PM
Oct-20-25 08:03AM
Oct-17-25 03:00PM
Oct-09-25 02:36PM
Oct-06-25 03:00PM
08:03AM
Sep-30-25 02:30PM
Sep-29-25 08:03AM
03:00PM Loading…
Sep-24-25 03:00PM
08:03AM
Sep-09-25 03:00PM
Sep-08-25 08:17AM
Sep-03-25 03:30PM
08:51AM
08:03AM
Sep-02-25 01:19PM
08:41AM
03:53AM
Aug-27-25 03:00PM
08:03AM
Aug-25-25 03:15PM
Aug-21-25 03:05AM
Aug-19-25 01:00PM
09:21AM Loading…
09:21AM
Aug-18-25 09:19AM
08:10AM
Aug-14-25 02:00PM
12:00PM
Aug-13-25 06:06PM
02:00PM
Aug-12-25 03:47PM
Aug-11-25 04:05PM
08:03AM
Aug-08-25 08:03AM
Aug-04-25 08:03AM
Jul-29-25 08:03AM
Jul-21-25 02:37PM
Jul-16-25 03:30PM
Jul-08-25 03:30PM
Jun-30-25 02:30PM
Jun-27-25 11:50AM
Jun-26-25 03:00PM
08:03AM
Jun-23-25 08:03AM
Jun-16-25 02:30PM
08:03AM
Jun-12-25 08:03AM
Jun-06-25 02:30PM
Jun-05-25 02:39PM
08:03AM
May-28-25 03:30PM
May-27-25 07:56PM
02:30PM
May-21-25 12:57PM
08:03AM
May-20-25 01:00PM
May-16-25 01:14PM
03:13AM
May-15-25 04:03PM
02:00PM
10:15AM
May-13-25 02:00PM
08:03AM
May-12-25 08:03AM
May-09-25 11:11AM
May-06-25 09:30AM
08:03AM
May-05-25 08:03AM
Apr-30-25 08:46AM
Apr-21-25 08:01AM
Apr-03-25 08:03AM
Mar-31-25 08:02AM
Mar-27-25 09:55AM
Mar-24-25 08:02AM
Mar-21-25 11:50AM
Mar-18-25 03:01AM
Mar-17-25 08:02AM
Mar-12-25 08:01AM
Mar-01-25 10:29AM
Feb-06-25 08:03AM
Feb-03-25 08:59AM
Jan-28-25 08:05AM
08:03AM
Jan-21-25 08:02AM
Jan-15-25 08:02AM
Jan-14-25 08:03AM
Jan-13-25 08:04AM
Jan-10-25 08:04AM
Jan-08-25 10:20AM
Jan-07-25 08:07AM
Jan-06-25 10:16AM
08:03AM
Jan-03-25 08:03AM
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Javitt Jonathan CChairman and Chief ScientistDec 17 '24Buy1.1740,00046,80084,634Dec 18 08:27 AM